LETTER
Systemic lupus erythematosus (SLE) is an inflammatory condition characterized by multiple organ involvement, antibodies against nuclear constituents and deposition and/or formation of immune complexes in affected organs (1) . The current treatment strategies intend to relieve symptoms, induce remission, or at least allay the disease activity, and prevent future flares and organ damage (2) . Belimumab, a monoclonal antibody that neutralize soluble B-lymphocyte stimulator (BLyS), is the first U.S. Food and Drug Administration-approved treatment for SLE in over 50 years (3) . In Europe, belimumab is indicated as adjunctive therapy in adult patients with active SLE despite standard of care (4) . Herein, we report one case with severe non-renal SLE that developed nephritis on belimumab treatment. Oral and written informed consent was obtained from the affected patient.
A non-smoking Caucasian woman born in 1951 with a history of cervical cancer in situ and enucleation of right eye due to malignant melanoma was referred to our unit in July 2004 on the suspicion of rheumatoid arthritis (RA). She had two successful pregnancies and one miscarriage, and suffered from arthralgias for many years. Interestingly, her mother was diagnosed with RA in her 60s but died due to rapidly progressive renal failure 10 years later (high levels of myeloperoxidase-ANCA were found, but renal biopsy was never performed). Autoantibody testing showed a positive homogeneous ANA, whereas anti-CCP and rheumatoid factor tests were negative. The consultant rheumatologist found symmetrical hand synovitis of metacarpophalangeal and proximal interphalangeal joints. No laboratory abnormalities, including complement, except for a low anti-dsDNA titre (1:10) detected by Crithidia luciliae test were recorded. Treatment 3 with a low daily dose oral prednisolone and hydroxychloroquine (HQ) 200 mg on the suspicion of SLE polyarthritis was introduced. Hand X-ray showed one single erosion. In 2007 the patient was affected by a conjunctival bleeding in her left eye. HQ was discontinued due to the patient's wish. Six months later she was doing well without HQ.
Anti-dsDNA was still positive at titre 1:10, whereas complement levels were normal.
In January 2008, the patient complained of stiffness and muscle pain. 20 mg prednisolone was temporarily re-introduced in tapering dosage. Two weeks later, she described chest pain with severe fatigue and arthralgias. Redness of the throat (no ulcers) was recorded, but no signs of synovitis. One week later, she still had flu-like muscle aches and fever. Classical complement function was slightly reduced to 70% (ref. In January 2011, the patient experienced shortness of breath and chest pain. Highresolution CT showed pleural effusion on left side, but no embolization. 40 mg prednisolone daily was required to resolve symptoms. Azathioprine was added, but soon ended due to elevated transaminases. During the next year, it was very difficult to reach reasonable doses of prednisolone due to pleuritic chest pain. Anti-dsDNA rose and 4 anti-C1q antibody levels reached the highest level measured to date at our laboratory.
Mycophenolate mofetil (MMF) was initiated, but ended due to nausea already after 1 month. Methotrexate was initiated, but terminated quickly due to headache.
In July 2012, the patient once again presented with pleural effusion and chest pain. during the study period (6, 7). Obviously, our patient was at high risk of renal involvement since she had been exposed to raised anti-dsDNA titres and complement consumption for a long time. The target for belimumab, BLyS, has indeed been detected in renal specimens of patients with active LN (8); and BLyS levels have been shown to associate with global lupus activity indices (9) . Thus, it is not unlikely that belimumab delayed the onset of LN in this particular patient, but the active serology was not significantly improved until she received cyclophosphamide. This case underlines that the assortment of a patient subgroup suitable for belimumab automatically selects individuals that are prone to -and at high risk of -developing LN. This is important to take into account, both in the selection of the "right" patients to receive belimumab in the everyday clinical practice and when designing further belimumab clinical trials. 
